NCT03658213View on ClinicalTrials.gov

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2020

Primary Completion Date

November 4, 2021

Study Completion Date

November 4, 2021

Conditions
Breast Cancer
Interventions
DRUG

ZOLADEX 10.8 mg

10.8 mg depot for injection (equivalent to 10.8 mg goserelin)

DRUG

ZOLADEX 3.6mg

3.6 mg depot for injection (equivalent to 3.6 mg goserelin)

Trial Locations (11)

100006

Research Site, Beijing

110016

Research Site, Shenyang

150081

Research Site, Harbin

200032

Research Site, Shanghai

300060

Research Site, Tianjin

310009

Research Site, Hangzhou

310022

Research Site, Hangzhou

510060

Research Site, Guangzhou

510100

Research Site, Guangzhou

610041

Research Site, Chengdu

050035

Research Site, Shijiazhuang

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY